KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Common Equity (2018 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Common Equity for 8 consecutive years, with $365.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity fell 5.73% year-over-year to $365.8 million, compared with a TTM value of $365.8 million through Sep 2025, down 5.73%, and an annual FY2024 reading of $377.5 million, changed 0.13% over the prior year.
  • Common Equity was $365.8 million for Q3 2025 at Aurinia Pharmaceuticals, up from $335.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $479.1 million in Q4 2021 and bottomed at $298.2 million in Q3 2021.
  • Average Common Equity over 5 years is $382.8 million, with a median of $378.0 million recorded in 2023.
  • The sharpest move saw Common Equity dropped 27.17% in 2021, then surged 42.01% in 2022.
  • Year by year, Common Equity stood at $479.1 million in 2021, then decreased by 15.37% to $405.4 million in 2022, then decreased by 6.78% to $378.0 million in 2023, then dropped by 0.13% to $377.5 million in 2024, then fell by 3.1% to $365.8 million in 2025.
  • Business Quant data shows Common Equity for AUPH at $365.8 million in Q3 2025, $335.3 million in Q2 2025, and $350.2 million in Q1 2025.